Intravenous Pyridorin

Treating Acute Kidney Injury

NephroGenex to develop I.V. form of Pyridorin for use in hospital-acquired acute kidney injury

Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality.

The major causes of hospital-acquired AKI are decreased renal perfusion during surgery, contrast nephropathy and cancer therapy with nephrotoxic drugs such as cisplatin.

These interventions are thought to induce injury, in part, by inducing oxidative stress in renal tissues characterized by the increased levels of reactive oxygen species (ROS) as well as reactive carbonyl species (RCS).

PYRIDORIN® has been shown to scavenge both ROS and RCS in vitro and in preclinical studies. In the proof of principle preclinical studies, Pyridorin treatment ameliorated renal oxidative stress and injury, enhanced functional recovery and reduced post-injury fibrosis in the ischemia-reperfusion mouse model of AKI.